Healthcare - Biotechnology - NASDAQ - US
$ 288.58
-4.66 %
$ 6.29 B
Market Cap
-11.53
P/E
CASH FLOW STATEMENT
-324 M
OPERATING CASH FLOW
-503 M
INVESTING CASH FLOW
595 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Madrigal Pharmaceuticals, Inc.
| Net Income | -374 M |
| Depreciation & Amortization | 527 K |
| Capital Expenditures | -1.48 M |
| Stock-Based Compensation | 49.7 M |
| Change in Working Capital | -3.28 M |
| Others | -5.07 M |
| Free Cash Flow | -326 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | Dec-2013 | Dec-2012 | Dec-2011 | Dec-2010 | Dec-2009 | Dec-2008 | Dec-2007 | Dec-2006 | Dec-2005 | Dec-2004 | Dec-2003 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||||||||||||||||
| Net Income | (373.6) | (295.4) | (241.8) | (202.2) | (83.9) | (32.8) | (31.2) | (26.4) | (68.7) | (86.2) | (90.2) | (62.8) | (47.4) | (37.5) | 79.1 | (92.6) | (63.5) | (57.3) | (68.9) | (45.9) | (27.9) |
| Depreciation & Amortization | 0.5 | 0.5 | 0.4 | 0.5 | 0.1 | 96 K | 77 K | 156 | 0.7 | 0.7 | 0.5 | 0.7 | 1.5 | 1.9 | 2.5 | 2.7 | 3.4 | 3.7 | 2.5 | 1.5 | 1.0 |
| Deferred Income Tax | 0 | 0 | (7.3) | (21.8) | (24.3) | 0 | 0 | 0 | 0 | 0 | (6.0) | 0 | 0 | 0 | 0 | (7.6) | (5.4) | (4.8) | 0 | 0 | 0 |
| Stock Based Compensation | 49.7 | 31.6 | 26.9 | 20.7 | 22.8 | 13.5 | 3.3 | 8.7 | 4.3 | 7.4 | 6.0 | 3.3 | 3.4 | 4.0 | 4.6 | 7.6 | 5.4 | 4.8 | 0 | 0 | 0 |
| Other Operating Activities | 2.4 | 0.8 | 7.3 | 21.8 | 24.3 | 13.1 | 2.5 | 1.2 | 3.5 | 3.12 K | 6.0 | 0 | 0 | 0 | 0 | 7.6 | 5.4 | 4.8 | 4.3 | 3.2 | 2.4 |
| Change in Working Capital | (3.3) | 37.6 | 30.7 | 23.5 | 19.5 | (6.3) | 5.5 | (1.1) | (7.7) | (0.9) | 6.2 | 4.6 | (4.7) | (6.7) | (112.9) | 44.4 | 81.9 | (4.2) | 0.3 | 7.4 | 0.9 |
| Cash From Operations | (324.2) | (224.9) | (183.9) | (157.6) | (41.6) | (25.5) | (22.3) | (17.6) | (71.4) | (78.9) | (77.4) | (54.1) | (47.3) | (38.2) | (26.8) | (37.9) | 27.2 | (53.0) | (61.9) | (33.8) | (23.6) |
| INVESTING CASH FLOW | |||||||||||||||||||||
| Capital Expenditures | (1.5) | (0.2) | (0.2) | (0.3) | (0.2) | 22 K | (0.1) | 3.08 K | 58 K | (0.1) | (0.8) | (0.5) | (0.7) | (0.1) | (0.5) | (2.2) | (2.4) | (1.6) | (4.9) | (1.6) | (0.8) |
| Other Items | (501.0) | 206.9 | (4.8) | 160.1 | 30.9 | (380.1) | (21.9) | 22.0 | 20.1 | (8.7) | (23.9) | (9.4) | 10.0 | (19.7) | 21.5 | (21.5) | 13.1 | 25.2 | 44.1 | (42.2) | (39.6) |
| Cash From Investing Activities | (502.5) | 206.7 | (5.1) | 159.8 | 30.7 | (380.1) | (22.0) | 22.0 | 20.0 | (8.8) | (24.7) | (9.9) | 9.3 | (19.8) | 21.0 | (23.7) | 10.8 | 23.6 | 39.2 | (43.8) | (40.4) |
| FINANCING CASH FLOW | |||||||||||||||||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 32 K | 0 | 0 | 0 | 0 | (0.3) | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 65.0 | 50.0 | 0 | 0 | 0 | 0 | 0 | 8.5 | 3.3 | (9.5) | 10.9 | (4.2) | 1.4 | 13.2 | (2.2) | (1.9) | (2.6) | (2.1) | (1.1) | (0.2) | 70 K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (1.9) | 0 | 0 | 0 |
| Other Financing Activities | 269.9 | 8.1 | 1.0 | 0.7 | 0.2 | 2.5 | 0 | 250 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.0 | 3.3 | 4.7 | 1.1 | 0 |
| Cash From Financing Activities | 595.1 | 313.5 | 171.2 | 5.1 | 0.2 | 314.3 | 173.8 | 14.5 | 40.4 | 85.3 | 69.0 | 115.5 | 36.7 | 45.2 | (2.1) | (1.9) | 43.9 | 39.3 | 3.8 | 84.3 | 71.1 |
| CHANGE IN CASH | |||||||||||||||||||||
| Net Change In Cash | (231.6) | 295.3 | (17.7) | 7.3 | (10.7) | (91.2) | 129.5 | 18.8 | (11.1) | (2.5) | (33.0) | 51.4 | (1.2) | (12.8) | (7.9) | (63.5) | 81.9 | 9.9 | (18.9) | 6.7 | 7.1 |
| FREE CASH FLOW | |||||||||||||||||||||
| Free Cash Flow | (325.7) | (225.1) | (184.1) | (157.9) | (41.8) | (25.5) | (22.4) | (17.6) | (71.5) | (79.1) | (78.2) | (54.6) | (48.0) | (38.3) | (27.3) | (40.1) | 24.9 | (54.6) | (66.8) | (35.4) | (24.4) |